API | interferon beta-1a

interferon beta-1a (Avonex) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

interferon beta-1a

interferon beta

More Chemistry

Pharmacology

Mechanisms of Action:
- Interferon alpha/beta receptor 1 (Homo sapiens) ^UniProt
- Interferon alpha/beta receptor 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Organizations (16)

Research & Development (13)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Multiple Sclerosis

Experimental Indications - Clinical Trial Phases 1-4 (5)

COVID-19 (Phase 3)

Dermatitis, Atopic (Phase 1)

Multiple Sclerosis ()

SARS-CoV-2 (Phase 3)

Severe acute respiratory syndrome-related coronavirus (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 13

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue